Patent classifications
C07D207/24
PROCESS FOR THE PREPARATION OF TROFINETIDE
Present invention relates to Trofinetide of Formula I having a purity of 99.0% or more and one or more of each of compound of Formula II, compound of Formula A, compound of Formula B, compound of Formula C, compound of Formula D, compound of Formula E, or compound of Formula F,
##STR00001## ##STR00002##
which when present, is in a detectable amount of about 0.15% or less, as measured by area percentage of HPLC. In particular, the present invention relates to novel intermediate compound of Formula II, process for the preparation of novel intermediate and use of novel intermediate compound in the preparation of trofinetide. Present invention further relates to use of trofinetide in the preparation of composition comprising trofinetide.
Heterocyclic inhibitors of MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: ##STR00001## Methods of inhibition MCT4 activity in a human or animal subject are also provided.
Heterocyclic inhibitors of MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: ##STR00001## Methods of inhibition MCT4 activity in a human or animal subject are also provided.
MASP-2 INHIBITORS AND METHODS OF USE
The present disclosure provides, intra alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
MASP-2 INHIBITORS AND METHODS OF USE
The present disclosure provides, intra alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
HETEROCYCLIC RING-SUBSTITUTED AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present disclosure relates to a substituted aromatic compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and use thereof for treating and/or preventing a disease or symptom in which a Kv1.3 potassium channel plays a role.
HETEROCYCLIC RING-SUBSTITUTED AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
The present disclosure relates to a substituted aromatic compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and use thereof for treating and/or preventing a disease or symptom in which a Kv1.3 potassium channel plays a role.
Lipid compounds and lipid nanoparticle compositions
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.